Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification
暂无分享,去创建一个
Mark J van der Laan | Maya L Petersen | Richard D Moore | M. J. van der Laan | M. Petersen | S. Deeks | J. Eron | Steven G Deeks | Sonia Napravnik | Joseph J Eron | S. Napravnik | M. Petersen | Richard D. Moore
[1] R. Elston,et al. Minimizing Resistance Consequences After Virologic Failure on Initial Combination Therapy: A Systematic Overview , 2006, Journal of acquired immune deficiency syndromes.
[2] C. Katlama,et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial , 2006, The Lancet.
[3] J. Robins,et al. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. , 2000, Epidemiology.
[4] Mark J van der Laan,et al. Deletion/Substitution/Addition Algorithm in Learning with Applications in Genomics , 2004, Statistical applications in genetics and molecular biology.
[5] M. Kazatchkine,et al. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. , 2001, The Journal of infectious diseases.
[6] B. Chi,et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. , 2006, JAMA.
[7] P. Harrigan,et al. Adherence–resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness , 2006, AIDS.
[8] Christopher D Pilcher,et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. , 2006, JAMA.
[9] M. Davidian,et al. Marginal structural models for analyzing causal effects of time-dependent treatments: an application in perinatal epidemiology. , 2004, American journal of epidemiology.
[10] M. Kozal,et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial , 2006, The Lancet.
[11] T. Wrin,et al. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. , 2002, The Journal of infectious diseases.
[12] J. Robins,et al. Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures , 2002, Statistics in medicine.
[13] R Hoh,et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. , 2001, The New England journal of medicine.
[14] J. Eron,et al. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients , 2007, AIDS.
[15] R. Stone,et al. Discordant Responses to Potent Antiretroviral Treatment in Previously Naive HIV-1-Infected Adults Initiating Treatment in Resource-Constrained Countries: The Antiretroviral Therapy in Low-Income Countries (ART-LINC) Collaboration , 2007, Journal of acquired immune deficiency syndromes.
[16] P. Harrigan,et al. Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART , 2006, PLoS medicine.
[17] S. Gove,et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings , 2006, The Lancet.
[18] Jeffrey N. Martin,et al. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia , 2002, AIDS.
[19] John W. Mellors,et al. Panel on Clinical Practices for Treatment of HIV Infection , 2000 .
[20] J. Robins,et al. Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.
[21] N. Ford,et al. HIV viral load monitoring in resource-limited regions: optional or necessary? , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] A. Telenti,et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. , 2007, Archives of internal medicine.
[23] Robert T. Schooley,et al. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. U.S. Department of Health and Human Services (DHHS). , 1997, BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation.
[24] Bruno Ledergerber,et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes , 2004, The Lancet.
[25] Eoin Coakley,et al. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] Michael S Saag,et al. Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel , 2006 .
[27] Martin S. Hirsch,et al. Treatment for adult HIV infection. , 2004 .
[28] S. Cole,et al. Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. , 2002, American journal of epidemiology.
[29] R. D’Aquila,et al. Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy , 2004, Journal of acquired immune deficiency syndromes.
[30] A. Hsu,et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. , 2004, The Journal of infectious diseases.
[31] N. Ford,et al. Scaling up antiretroviral treatment in resource-poor settings , 2006, The Lancet.
[32] M. Hirsch,et al. Monitoring HIV treatment in developing countries , 2006, BMJ : British Medical Journal.
[33] Jonathan AC Sterne,et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study , 2005, The Lancet.